Damon Mcknight
Australia is witnessing a significant rise in the prevalence of Multiple Sclerosis (MS), a chronic disease that attacks the central nervous system. MS Australia, the national peak body for people affected by MS, has reported an increasing number of cases, with over 33,000 Australians affected as of 2022. The southern states of Australia have a higher prevalence of MS compared to the northern regions. The condition affects three times more women than men in the country, and the availability of resources for treatment and management is a growing concern. MS Australia provides care and support services, including referral advice, individual assessments, and support for employment and living arrangements. The organisation also advocates for people with MS, such as successfully lobbying the government for electricity subsidies to combat heat intolerance, a worsening factor for MS symptoms. Additionally, Australia offers a range of educational opportunities for international students seeking a Master of Science (MS) degree, with competitive salaries and a diverse selection of courses.
| Characteristics | Values |
|---|---|
| Number of Australians with MS | 33,335 in 2021, up from 25,607 in 2017 |
| Prevalence per 100,000 Australians | 136.1 in 2021, up from 103.7 in 2017 |
| MS as a neurological disease | Most common acquired chronic neurological disease affecting young adults |
| Gender distribution | Affects three times more women than men |
| Treatment options | 15 disease-modifying therapies available, with most covered by the Pharmaceutical Benefits Scheme (PBS) |
| Diagnosis age | Often between 20 and 40 years |
| Oral health concerns | 75% of respondents with MS experienced two or more oral health issues in a year |
| Employment rate | 57.8% employment rate for people with MS in 2013, compared to the general population |
| Workplace attendance | Average of 3.4% of potential workdays missed due to MS symptoms |
| MS organisations in Australia | MS Australia, state/territory-based support organisations |
| Average salary for MS graduates | AUD 85,000 per year |
Explore related products
What You'll Learn
- MS Australia provides support and resources for people living with MS
- MS affects three times more women than men in Australia
- MS is the most common chronic neurological disease in young adults
- MS prevalence is higher in southern Australian states
- MS treatments: 15 disease-modifying therapies are available
MS Australia provides support and resources for people living with MS
MS Australia is the national peak body for people affected by MS and is committed to advocacy, communication, education, and funding and coordinating multiple sclerosis (MS) research. The organisation provides care and support services to people living with MS and other neurological and immunological conditions. This includes referral advice and information, individual assessments and support, employment support, living arrangements, and connection with others.
MS Australia also offers a range of resources to help people living with MS, including a podcast, videos, and a guide called 'Living Well with MS', which provides practical advice on lifestyle choices. Additionally, they have created a 'What is MS?' video to educate the general public and people living with MS about the causes, different types, and symptoms of the disease.
The organisation also provides information on government-funded supports and benefits available to people living with MS, such as the National Disability Insurance Scheme (NDIS), which provides funding to support people with permanent disabilities, including MS, who are under 65 years old. The Disability Gateway is another resource that helps people with disabilities, their families, and carers navigate, locate, and access services across Australia. For those aged 65 and above, My Aged Care provides access to residential aged care and assessment.
MS Australia also works closely with state and territory-based MS organisations, which offer additional support and services tailored to the specific needs of people living with MS in their respective regions. These organisations play a crucial role in providing care and expertise in the diagnosis and management of multiple sclerosis.
How the Dutch Discovered Australia: A Historical Overview
You may want to see also
Explore related products
MS affects three times more women than men in Australia
Multiple sclerosis (MS) is a chronic disease that attacks the central nervous system, including the brain, spinal cord, and optic nerves. It is the most common acquired chronic neurological disease affecting young adults in Australia, with over 25,000 diagnosed cases in the country. Notably, MS affects three times more women than men in Australia, a trend that has been observed in other countries as well. This gender disparity is a focus of ongoing research, with several factors being considered.
In Australia, the number of people living with MS is increasing, with an estimated prevalence of 136.1 people living with MS per 100,000 Australians in 2021, up from 103.7 per 100,000 in 2017. This rise in prevalence has implications for the resources required to treat and manage MS effectively. The availability and accessibility of treatments and care, such as disease-modifying therapies (DMTs) and MS specialist nurses, are crucial considerations.
While the exact cause of MS remains unknown, a combination of genetic and environmental factors is believed to contribute to its development. Research has indicated that factors such as smoking and vitamin D levels may play a role in the onset of MS. Additionally, the impact of sex hormones on the immune response to certain viruses is also being explored as a potential contributor to the higher prevalence of MS in women.
The symptoms of MS can vary widely, and no two people experience the disease in the same way. However, depression has been found to be three times more common in people with MS compared to the general population. As such, managing mental health and brain health is crucial for individuals living with MS, and early treatment for depression is key to successful management.
Although there is currently no cure for MS, the MS landscape has seen significant progress in recent years due to advancements in research and therapeutics. There are now 15 disease-modifying therapies available in Australia, and early diagnosis has improved, leading to better long-term outcomes for patients. MS Australia, the national peak body for people affected by MS, plays a vital role in advocacy, communications, education, and funding research to solve MS.
Australia's Burqa Ban: What's the Story?
You may want to see also
Explore related products
MS is the most common chronic neurological disease in young adults
Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, including the brain, spinal cord, and optic nerves. It is the most common chronic neurological disease in young adults, often diagnosed between the ages of 20 and 40. In Australia, MS affects three times as many women as men, and the prevalence is higher in the southern states compared to the northern regions.
The number of Australians living with MS is increasing, with a significant and accelerating growth rate. In 2021, there were an estimated 33,335 people living with MS in Australia, up from 25,607 in 2017 and 21,238 in 2010. This rise in prevalence has implications for the resources needed to treat and manage MS, including the cost, availability, and accessibility of treatments and care.
MS Australia, the national peak body for people affected by MS, is dedicated to advocacy, communications, education, and funding research. They provide care and support services, including referral advice, individual assessments, employment support, and connection with others. MS Australia has also been instrumental in lobbying the government for electricity subsidies and assistance for people with MS to combat heat intolerance, as heat can worsen MS symptoms.
While there is currently no cure for MS, the MS landscape has been transformed in recent years by advancements in research and therapeutics. There are now 15 disease-modifying therapies available in Australia, and people with MS are being diagnosed earlier, leading to improved long-term outcomes. However, for progressive MS, treatment options remain limited, highlighting the ongoing need for investment in research and treatment development.
MS can impact various aspects of daily living, including oral health and employment. People with MS may face challenges in maintaining good oral health due to physical symptoms and side effects from medication. Additionally, while advancements have been made to support workplace participation for those with MS, some employed individuals still report a loss of productivity while at work. Overall, MS is a complex and often invisible disease that significantly affects the lives of those diagnosed, making ongoing research and support crucial.
Magic Mike's Australian Rating: Suitable Only for Adults
You may want to see also
Explore related products
$53.19 $55.99
MS prevalence is higher in southern Australian states
Multiple sclerosis (MS) is a chronic disease that attacks the central nervous system, including the brain, spinal cord, and optic nerves. It is the most common acquired chronic neurological disease affecting young adults, often diagnosed between the ages of 20 and 40. In Australia, MS affects three times more women than men, and its prevalence is increasing across the country.
The number of Australians living with MS is rising over time, both nationally and in most states and territories. Notably, the estimated prevalence of MS is higher in the southern states compared to the northern regions. This disparity has significant implications for resource allocation to treat and manage MS effectively.
The Health Economic Impact of Multiple Sclerosis in Australia report revealed notable increases in the number of people living with MS. In 2021, there were 33,335 Australians with MS, a significant jump from 25,607 in 2017 and 21,238 in 2010. The increase from 2017 to 2021 was 7,728, a much larger rise than the 4,324 increase between 2010 and 2017.
While the overall prevalence of MS is rising across Australia, the southern states stand out with a higher concentration of cases. This trend underscores the need for dedicated resources and support services in those regions. The state and territory-based MS organisations in Australia play a crucial role in providing care and support to individuals living with MS and other neurological and immunological conditions.
The rising prevalence of MS in the southern Australian states has prompted researchers to investigate this phenomenon further. The calculation of new prevalence estimates for 2024 will be included in the upcoming Health Economic Impact report, in collaboration with MS Australia. This ongoing research is vital for understanding the evolving landscape of MS and ensuring that sufficient resources are allocated to address the needs of those living with the disease.
Uncover Missing Money in Australia: Tips to Find Your Cash
You may want to see also
Explore related products
MS treatments: 15 disease-modifying therapies are available
Multiple sclerosis (MS) is the most common chronic neurological disease affecting young adults in Australia. It is an autoimmune condition where the body's immune system mistakenly attacks the protective covering of nerve fibres, called myelin, which is important for allowing electrical impulses to travel quickly and efficiently from the brain to the rest of the body. While there is currently no cure for MS, there are disease-modifying therapies (also known as immunotherapies or disease-modifying drugs) that can help manage symptoms and slow the progression of the disease.
In Australia, there are 15 disease-modifying therapies available for people with MS, and most of these are listed on the Pharmaceutical Benefits Scheme (PBS). This means that the cost to the patient for the generic brand medicine is likely to be the same as the original brand name version. The choice of medication depends on various factors, including the type of MS and individual circumstances.
Disease-modifying therapies reduce the frequency and severity of attacks on the brain and spinal cord, thereby reducing the number of relapses (or flare-ups) and slowing down the progression of the disease. They are most commonly prescribed for relapsing-remitting MS, where they have been shown to have the greatest impact. Other types of medications for MS include corticosteroids, which are used during acute relapses to reduce inflammation and provide symptom relief, and symptomatic treatments, which address specific symptoms such as incontinence, muscle spasticity, pain, or depression.
While there have been advances in the science of MS detection and treatment, there is still a need to better monitor the effectiveness of treatments and to better target the care received by individual patients. For example, Associate Professor Maria Markoulli from the School of Optometry and Vision Science is conducting studies to develop a new way of monitoring inflammation in MS patients via the eye. Additionally, MS Australia does not recommend any specific treatment for people living with MS, and decisions about treatments should be made in careful consultation with a neurologist.
Improving Dental Health in Australia on a Budget
You may want to see also
Frequently asked questions
According to PayScale, the average salary for a graduate in Australia after doing an MS is AUD 85,000 per year. However, other sources state that the average salary for a fresh graduate in Australia is AUD 72,000 per year.
The tuition fee for master's programs in Australia can range from AUD 22,000 to AUD 50,000 per year. Living costs depend on your lifestyle, but can be expected to be between AUD 11,000 and AUD 22,000 per year. On-campus accommodation can cost between AUD 110 and AUD 280 per week.
Multiple sclerosis (MS) is a chronic disease that attacks the central nervous system. It is the most common acquired chronic neurological disease affecting young adults in Australia, often diagnosed between the ages of 20 and 40. The number of Australians living with MS is increasing, with an estimated prevalence of 136.1 people living with MS per 100,000 Australians in 2021, up from 103.7 in 2017.
